✦ LIBER ✦

Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease

✍ Scribed by MÃ¼ller, Thomas; Hoffmann, Josef A.; Dimpfel, Walter; Oehlwein, Christian

Book ID: 120383960
Publisher: Springer
Year: 2012
Tongue: English
Weight: 181 KB
Volume: 120
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s00702-012-0927-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tolerability and efficacy of switching f

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson’s disease

✍ William G. Ondo; Christine Hunter; Stuart H. Isaacson; Dee E. Silver; R. Malcolm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 101 KB

PND37 An Examination of Resource Utiliza

PND37 An Examination of Resource Utilization Among Patients with Parkinson'S Disease Treated with Rasagiline or Selegiline

✍ E. Grubb; J. Castelli-Haley; M. Lage 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Selegiline and blood pressure in patient

Selegiline and blood pressure in patients with Parkinson's disease

✍ V. Pursiainen; T. J. Korpelainen; H. T. Haapaniemi; A. K. Sotaniemi; V. V. Myll 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 494 KB

Switching from pergolide to pramipexole

Switching from pergolide to pramipexole in patients with Parkinson's disease

✍ P. A. Hanna; L. Ratkos; W. G. Ondo; J. Jankovic 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 100 KB

Administration of selegiline is not asso

Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients

✍ S. Papapetropoulos; A.A. Argyriou 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Rasagiline improves quality of life in p

Rasagiline improves quality of life in patients with early Parkinson's disease

✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P